Abstract
Astemizole is a H1-antagonist endowed with antimalarial activity, but has hERG liabilities. Systematic structural modifications of astemizole led to the discovery of analogues that display very potent activity as inhibitors of the growth of the Plasmodium parasite, but show a decreased hERG inhibition, when compared to astemizole. These compounds can be used as starting point for the development of a new class of antimalarials.
Copyright © 2017 Elsevier Ltd. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antimalarials / chemical synthesis
-
Antimalarials / chemistry
-
Antimalarials / pharmacology*
-
Astemizole / chemical synthesis
-
Astemizole / chemistry
-
Astemizole / pharmacology*
-
Dose-Response Relationship, Drug
-
Humans
-
Molecular Structure
-
Parasitic Sensitivity Tests
-
Plasmodium falciparum / drug effects*
-
Plasmodium falciparum / growth & development
-
Structure-Activity Relationship
-
Transcriptional Regulator ERG / antagonists & inhibitors
-
Transcriptional Regulator ERG / metabolism
Substances
-
Antimalarials
-
ERG protein, human
-
Transcriptional Regulator ERG
-
Astemizole